journal
https://read.qxmd.com/read/38770775/consensus-review-on-strategies-to-improve-delivery-across-the-bbb-including-focused-ultrasound
#1
JOURNAL ARTICLE
Keaton Piper, Jay I Kumar, Joseph Domino, Chad Tuchek, Michael A Vogelbaum
Drug delivery to the central nervous system (CNS) has been a major challenge for CNS tumors due to the impermeability of the blood brain barrier (BBB). There have been a multitude of techniques aimed at overcoming the BBB obstacle aimed at utilizing natural transport mechanisms or bypassing the BBB which we review here. Another approach that has generated recent interest in the recently published literature is to use new technologies (Laser Interstitial Thermal Therapy, LITT; or Low Intensity Focused Ultrasound, LIFU) to temporarily increase BBB permeability...
May 21, 2024: Neuro-oncology
https://read.qxmd.com/read/38769725/unraveling-the-hypoxic-puzzle-lncrna-lucat1-drives-glioblastoma-in-cooperation-with-hif1%C3%A2-%C2%BA
#2
EDITORIAL
Ying Zhang, Kadie Hudson, Roger Abounader
No abstract text is available yet for this article.
May 21, 2024: Neuro-oncology
https://read.qxmd.com/read/38769022/towards-consistency-in-pediatric-brain-tumor-measurements-challenges-solutions-and-the-role-of-ai-based-segmentation
#3
JOURNAL ARTICLE
Ariana M Familiar, Anahita Fathi Kazerooni, Arastoo Vossough, Jeffrey B Ware, Sina Bagheri, Nastaran Khalili, Hannah Anderson, Debanjan Haldar, Phillip B Storm, Adam C Resnick, Benjamin H Kann, Mariam Aboian, Cassie Kline, Michael Weller, Raymond Y Huang, Susan M Chang, Jason R Fangusaro, Lindsey M Hoffman, Sabine Mueller, Michael Prados, Ali Nabavizadeh
MR imaging is central to the assessment of tumor burden and changes over time in neuro-oncology. Several response assessment guidelines have been set forth by the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groups in different tumor histologies; however, the visual delineation of tumor components using MRIs is not always straightforward, and complexities not currently addressed by these criteria can introduce inter- and intra-observer variability in manual assessments. Differentiation of non-enhancing tumor from peritumoral edema, mild enhancement from absence of enhancement, and various cystic components can be challenging; particularly given a lack of sufficient and uniform imaging protocols in clinical practice...
May 21, 2024: Neuro-oncology
https://read.qxmd.com/read/38743009/resistance-rebound-and-recurrence-regrowth-patterns-in-pediatric-low-grade-glioma-treated-by-mapk-inhibition-a-modified-delphi-approach-to-build-international-consensus-based-definitions-international-pediatric-low-grade-glioma-coalition
#4
JOURNAL ARTICLE
Patricia O'Hare, Tabitha Cooney, Peter de Blank, David H Gutmann, Mark Kieran, Till Milde, Jason Fangusaro, Michael Fisher, Shivaram Avula, Roger Packer, Kohei Fukuoka, Kshitij Mankad, Sabine Mueller, Angela J Waanders, Enrico Opocher, Eric Bouffet, Eric Raabe, Natacha Entz Werle, Amedeo A Azizi, Nathan J Robison, Pablo Hernáiz Driever, Mark Russo, Netteke Schouten, Cornelis M van Tilburg, Astrid Sehested, Jacques Grill, Pratiti Bandopadhayay, John-Paul Kilday, Olaf Witt, David M Ashley, Birgit Betina Ertl-Wagner, Uri Tabori, Darren R Hargrave
Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor group. The natural history, when curative resection is not possible, is one of a chronic disease with periods of tumor stability and episodes of tumor progression. While there is a high overall survival rate, many patients experience significant and potentially lifelong morbidities. The majority of pLGGs have an underlying activation of the RAS/MAPK pathway due to mutational events, leading to the use of molecularly targeted therapies in clinical trials, with recent regulatory approval for the combination of BRAF and MEK inhibition for BRAFV600E mutated pLGG...
May 14, 2024: Neuro-oncology
https://read.qxmd.com/read/38742275/a-triad-between-sex-necrosis-and-inflammation-shapes-glioblastoma-outcomes
#5
EDITORIAL
Brandon Emanuel León, Defne Bayik
No abstract text is available yet for this article.
May 14, 2024: Neuro-oncology
https://read.qxmd.com/read/38721826/smyd2-induced-pgc1%C3%AE-methylation-promotes-stemness-maintenance-of-glioblastoma-stem-cells
#6
JOURNAL ARTICLE
Mengdie Li, Zhixiang Zhang, Liuguijie He, Xiefeng Wang, Jianxing Yin, Xiuxing Wang, Yongping You, Xu Qian, Xin Ge, Zhumei Shi
BACKGROUND: The high fatality rate of glioblastoma (GBM) is attributed to glioblastoma stem cells (GSCs), which exhibit heterogeneity and therapeutic resistance. Metabolic plasticity of mitochondria is the hallmark of GSCs. Targeting mitochondrial biogenesis of GSCs is crucial for improving clinical prognosis in GBM patients. METHODS: SMYD2-induced PGC1α methylation and followed nuclear export is confirmed by co-immunoprecipitation, cellular fractionation, and immunofluorescence...
May 9, 2024: Neuro-oncology
https://read.qxmd.com/read/38718145/corrigendum-to-interim-fdg-pet-improves-treatment-failure-prediction-in-primary-central-nervous-system-lymphoma-an-loc-network-prospective-multicentric-study
#7
(no author information available yet)
No abstract text is available yet for this article.
May 8, 2024: Neuro-oncology
https://read.qxmd.com/read/38717379/gliomatosis-cerebri-in-children-a-poor-prognostic-phenotype-of-diffuse-gliomas-with-a-distinct-molecular-profile
#8
JOURNAL ARTICLE
Gunther Nussbaumer, Martin Benesch, Yura Grabovska, Alan Mackay, David Castel, Jacques Grill, Marta M Alonso, Manila Antonelli, Simon Bailey, Joshua N Baugh, Veronica Biassoni, Mirjam Blattner Johnson, Alberto Broniscer, Andrea Carai, Giovanna Stefania Colafati, Niclas Colditz, Selim Corbacioglu, Shauna Crampsie, Natacha Entz-Werle, Matthias Eyrich, Lea L Friker, Michael C Frühwald, Maria Luisa Garrè, Nicolas U Gerber, Felice Giangaspero, Maria J Gil-da-Costa, Norbert Graf, Darren Hargrave, Peter Hauser, Ulrich Herrlinger, Marion Hoffmann, Esther Hulleman, Elisa Izquierdo, Sandra Jacobs, Michael Karremann, Antonis Kattamis, Rejin Kebudi, Rolf-Dieter Kortmann, Robert Kwiecien, Maura Massimino, Angela Mastronuzzi, Evelina Miele, Giovanni Morana, Claudia M Noack, Virve Pentikainen, Thomas Perwein, Stefan M Pfister, Torsten Pietsch, Kleoniki Roka, Sabrina Rossi, Stefan Rutkowski, Elisabetta Schiavello, Clemens Seidel, Jaroslav Štěrba, Dominik Sturm, David Sumerauer, Anna Tacke, Sara Temelso, Chiara Valentini, Dannis van Vuurden, Pascale Varlet, Sophie E M Veldhuijzen van Zanten, Maria Vinci, André O von Bueren, Monika Warmuth-Metz, Pieter Wesseling, Maria Wiese, Johannes E A Wolff, Josef Zamecnik, Andrés Morales La Madrid, Brigitte Bison, Gerrit H Gielen, David T W Jones, Chris Jones, Christof M Kramm
BACKGROUND: The term Gliomatosis cerebri (GC), a radiology-defined highly infiltrating diffuse glioma, has been abandoned since molecular GC-associated features have not been established yet. METHODS: We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive clinical and (epi-)genetic characterization. RESULTS: Median overall survival (OS) was 15.5 months (interquartile range, 10.9-27...
May 8, 2024: Neuro-oncology
https://read.qxmd.com/read/38712642/corrigendum-to-the-surgical-management-of-diffuse-gliomas-current-state-of-neurosurgical-management-and-future-directions
#9
(no author information available yet)
No abstract text is available yet for this article.
May 7, 2024: Neuro-oncology
https://read.qxmd.com/read/38702966/radioligand-therapies-in-meningioma-evidence-and-future-directions
#10
JOURNAL ARTICLE
Maximilian J Mair, Emeline Tabouret, Derek R Johnson, Erik P Sulman, Patrick Y Wen, Matthias Preusser, Nathalie L Albert
Meningiomas are the most common intracranial neoplasms in adults. While most meningiomas are cured by resection, further treatment by radiotherapy may be needed, particularly in WHO grade 2 and 3 tumors which have an increased risk of recurrence, even after conventional therapies. Still, there is an urgent need for novel therapeutic strategies after exhaustion of local treatment approaches. Radionuclide therapies combine the specificity of tumor-specific antibodies or ligands with the cytotoxic activity of radioactive emitters...
May 4, 2024: Neuro-oncology
https://read.qxmd.com/read/38695575/meningioma-international-consortium-on-meningiomas-icom-consensus-review-on-scientific-advances-treatment-paradigms-for-clinicians-researchers-and-patients
#11
JOURNAL ARTICLE
Justin Z Wang, Alexander P Landry, David R Raleigh, Felix Sahm, Kyle M Walsh, Roland Goldbrunner, Leeor S Yefet, Jörg C Tonn, Chloe Gui, Quinn T Ostrom, Jill Barnholtz-Sloan, Arie Perry, Yosef Ellenbogen, C Oliver Hanemann, Gerhard Jungwirth, Michael D Jenkinson, Ghazaleh Tabatabai, Tiit I Mathiesen, Michael W McDermott, Marcos Tatagiba, Christian la Fougère, Sybren L N Maas, Norbert Galldiks, Nathalie L Albert, Priscilla K Brastianos, Felix Ehret, Giuseppe Minniti, Katrin Lamszus, Franz L Ricklefs, Jens Schittenhelm, Katharine J Drummond, Ian F Dunn, Omar N Pathmanaban, Aaron Cohen-Gadol, Erik P Sulman, Emeline Tabouret, Emelie Le Rhun, Christian Mawrin, Jennifer Moliterno, Michael Weller, Wenya Linda Bi, Andrew Gao, Stephen Yip, Maximilian Niyazi, Kenneth Aldape, Patrick Y Wen, Susan Short, Matthias Preusser, Farshad Nassiri, Gelareh Zadeh
Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and the rising availability of neuroimaging. While most exhibit non-malignant behaviour, a subset of meningiomas are biologically aggressive and lead to significant neurological morbidity and mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication...
May 2, 2024: Neuro-oncology
https://read.qxmd.com/read/38695342/immunotherapy-drives-mesenchymal-tumour-cell-state-shift-and-tme-immune-response-in-glioblastoma-patients
#12
JOURNAL ARTICLE
Josephine D Hendriksen, Alessio Locallo, Simone Maarup, Olivia Debnath, Naveed Ishaque, Benedikte Hasselbach, Jane Skjøth-Rasmussen, Christina Westmose Yde, Hans S Poulsen, Ulrik Lassen, Joachim Weischenfeldt
BACKGROUND: Glioblastoma is a highly aggressive type of brain tumour for which there is no curative treatment available. Immunotherapies have shown limited responses in unselected patients, and there is an urgent need to identify mechanisms of treatment resistance to design novel therapy strategies. METHODS: Here we investigated the phenotypic and transcriptional dynamics at single-cell resolution during nivolumab immune checkpoint treatment of glioblastoma patients...
May 2, 2024: Neuro-oncology
https://read.qxmd.com/read/38683135/eda2r-reflects-the-acute-brain-response-to-cranial-irradiation-in-liquid-biopsies
#13
JOURNAL ARTICLE
Alejandro Lastra Romero, Thea Seitz, Georgios Alkis Zisiadis, Holli Jeffery, Ahmed M Osman
BACKGROUND: Cranial radiotherapy is standard of care for high-grade brain tumors and metastases; however, it induces debilitating neurocognitive impairments in cancer survivors, especially children. As the numbers of pediatric brain cancer survivors continue improving, the numbers of individuals developing life-long neurocognitive sequalae are consequently expected to rise. Yet, there are no established biomarkers estimating the degree of the irradiation-induced brain injury at completion of radiotherapy to predict the severity of the expected neurocognitive complications...
April 29, 2024: Neuro-oncology
https://read.qxmd.com/read/38656347/phase-i-trial-of-dose-escalation-for-preoperative-stereotactic-radiosurgery-for-patients-with-large-brain-metastases
#14
JOURNAL ARTICLE
Erin S Murphy, Kailin Yang, John H Suh, Jennifer S Yu, Glen Stevens, Lilyana Angelov, Michael A Vogelbaum, Gene H Barnett, Manmeet S Ahluwalia, Gennady Neyman, Alireza M Mohammadi, Samuel T Chao
BACKGROUND: Single session stereotactic radiosurgery (SRS) or surgical resection alone for brain metastases larger than 2 cm results in unsatisfactory local control. We conducted a phase I trial for brain metastases(>2cm) to determine the safety of preoperative SRS at escalating doses. METHODS: Radiosurgery dose was escalated at 3 Gy increments for 3 cohorts based on maximum tumor dimension starting at: 18 Gy for >2-3 cm, 15 Gy for >3-4 cm, and 12 Gy for >4-6 cm...
April 24, 2024: Neuro-oncology
https://read.qxmd.com/read/38628133/very-long-term-outcomes-of-pediatric-patients-treated-for-optic-pathway-gliomas-a-longitudinal-cohort-study
#15
EDITORIAL
Roger J Packer
No abstract text is available yet for this article.
April 17, 2024: Neuro-oncology
https://read.qxmd.com/read/38607967/nf1-mutation-driven-neuronal-hyperexcitability-sets-a-threshold-for-tumorigenesis-and-therapeutic-targeting-of-murine-optic-glioma
#16
JOURNAL ARTICLE
Corina Anastasaki, Jit Chatterjee, Joshua P Koleske, Yunqing Gao, Stephanie L Bozeman, Chloe M Kernan, Lara I Marco Y Marquez, Ji-Kang Chen, Caitlin E Kelly, Connor J Blair, Dennis J Dietzen, Robert A Kesterson, David H Gutmann
BACKGROUND: With the recognition that noncancerous cells function as critical regulators of brain tumor growth, we recently demonstrated that neurons drive low-grade glioma initiation and progression. Using mouse models of neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG), we showed that Nf1 mutation induces neuronal hyperexcitability and midkine expression, which activates an immune axis to support tumor growth, such that high-dose lamotrigine treatment reduces Nf1-OPG proliferation...
April 12, 2024: Neuro-oncology
https://read.qxmd.com/read/38598668/liquid-biopsy-for-improving-diagnosis-and-monitoring-of-cns-lymphomas-a-rano-review
#17
JOURNAL ARTICLE
Lakshmi Nayak, Chetan Bettegowda, Florian Scherer, Norbert Galldiks, Manmeet Ahluwalia, Alexander Baraniskin, Louisa von Baumgarten, Jacoline E C Bromberg, Andrés J M Ferreri, Christian Grommes, Khê Hoang-Xuan, Julia Kühn, James L Rubenstein, Roberta Rudà, Michael Weller, Susan M Chang, Martin J van den Bent, Patrick Y Wen, Riccardo Soffietti
BACKGROUND: The utility of liquid biopsies is well documented in several extracranial and intracranial (brain/leptomeningeal metastases, gliomas) tumors. METHODS: The RANO (Response Assessment in Neuro-Oncology) group has set up a multidisciplinary Task Force to critically review the role of blood and CSF-liquid biopsy in central nervous system lymphomas, with a main focus on primary central nervous system lymphomas (PCNSL). RESULTS: Several clinical applications are suggested: diagnosis of PCNSL in critical settings (elderly or frail patients, deep locations, steroids responsiveness), definition of minimal residual disease, early indication of tumor response or relapse following treatments and prediction of outcome...
April 10, 2024: Neuro-oncology
https://read.qxmd.com/read/38595122/predicting-the-risk-of-neurocognitive-decline-after-brain-irradiation-in-adult-patients-with-a-primary-brain-tumor
#18
JOURNAL ARTICLE
Fariba Tohidinezhad, Catharina M L Zegers, Femke Vaassen, Jeanette Dijkstra, Monique Anten, Wouter Van Elmpt, Dirk De Ruysscher, Andre Dekker, Daniëlle B P Eekers, Alberto Traverso
BACKGROUND: Deterioration of neurocognitive function in adult patients with a primary brain tumor is the most concerning side effect of radiotherapy. This study was aimed to develop and evaluate Normal-Tissue Complication Probability (NTCP) models using clinical and dose-volume measures for 6-month, 1-year and 2-year Neurocognitive Decline (ND) post-radiotherapy. METHODS: A total of 219 patients with a primary brain tumor treated with radical photon and/or proton radiotherapy (RT) between 2019 and 2022 were included...
April 10, 2024: Neuro-oncology
https://read.qxmd.com/read/38592708/locoregional-delivery-of-car-t-cells-breaking-the-spell-in-glioblastoma
#19
JOURNAL ARTICLE
Marjolein Geurts, Matthias Preusser
No abstract text is available yet for this article.
April 9, 2024: Neuro-oncology
https://read.qxmd.com/read/38588460/demonstrated-efficacy-and-mechanisms-of-sensitivity-of-onc201-h3k27m-mutant-diffuse-midline-glioma-in-the-spotlight
#20
JOURNAL ARTICLE
Isabel Arrillaga-Romany, Julie J Miller
No abstract text is available yet for this article.
April 8, 2024: Neuro-oncology
journal
journal
34661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.